Literature DB >> 25973018

Elevated HMGB1-related interleukin-6 is associated with dynamic responses of monocytes in patients with active pulmonary tuberculosis.

Jin-Cheng Zeng1, Wen-Yu Xiang2, Dong-Zi Lin3, Jun-Ai Zhang4, Gan-Bin Liu3, Bin Kong2, Yu-Chi Gao2, Yuan-Bin Lu2, Xian-Jing Wu5, Lai-Long Yi3, Ji-Xin Zhong6, Jun-Fa Xu1.   

Abstract

There were limited studies assessing the role of HMGB1 in TB infection. In this prospective study, we aimed to assess the levels of HMGB1 in plasma or sputum from active pulmonary tuberculosis (APTB) patients positive for Mtb culture test, and to evaluate its relationship with inflammatory cytokines and innate immune cells. A total of 36 sputum Mtb culture positive APTB patients and 32 healthy volunteers (HV) were included. Differentiated THP-1 cells were treated for 6, 12 and 24 hrs with BCG at a multiplicity of infection of 10. The absolute values and percentages of white blood cells (WBC), neutrophils, lymphocytes, and monocytes were detected by an automatic blood analyzer. Levels of HMGB1, IL-6, IL-10 and TNF-α in plasma, sputum, or cell culture supernatant were measured by ELISA. The blood levels of HMGB1, IL-6, IL-10 and TNF-α, the absolute values of WBC, monocytes and neutrophils, and the percentage of monocytes were significant higher in APTB patients than those in HV groups (P < 0.05). The sputum levels of HMGB1, IL-10, and TNF-α were also significantly higher in APTB patients than those in HV groups (P < 0.05). Meanwhile, plasma level of HMGB1, IL-6, and IL-10 in APTB patients were positively correlated with those in sputum (P < 0.05), respectively. IL-6 was positively correlated with HMGB1 both in plasma and sputum of APTB patients (P < 0.05). HMGB1 and IL-6 is positively correlated with the absolute number of monocytes in APTB patients (P < 0.05). BCG induced HMGB1, IL-6, IL-10 and TNF-α production effectively in PMA-treated THP-1 cells. HMGB1 may be used as an attractive biomarker for APTB diagnosis and prognosis and may reflect the inflammatory status of monocytes in patients with APTB.

Entities:  

Keywords:  Active pulmonary tuberculosis; HMGB1; cytokines; immunity; infection

Mesh:

Substances:

Year:  2015        PMID: 25973018      PMCID: PMC4396284     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  61 in total

1.  Immune gene networks of mycobacterial vaccine-elicited cellular responses and immunity.

Authors:  Dan Huang; Liyou Qiu; Richard Wang; Xioamin Lai; George Du; Probhat Seghal; Yun Shen; Lingyun Shao; Lisa Halliday; Jeff Fortman; Ling Shen; Norman L Letvin; Zheng W Chen
Journal:  J Infect Dis       Date:  2006-11-22       Impact factor: 5.226

2.  Changes in leucocyte and lymphocyte subsets during tuberculosis treatment; prominence of CD3dimCD56+ natural killer T cells in fast treatment responders.

Authors:  H Veenstra; R Baumann; N M Carroll; P T Lukey; M Kidd; N Beyers; C T Bolliger; P D van Helden; G Walzl
Journal:  Clin Exp Immunol       Date:  2006-08       Impact factor: 4.330

3.  Extracellular HMGB1 regulates multi-walled carbon nanotube-induced inflammation in vivo.

Authors:  Forrest Jessop; Andrij Holian
Journal:  Nanotoxicology       Date:  2014-07-01       Impact factor: 5.913

4.  TNF-alpha, TGF-beta and NO relationship in sera from tuberculosis (TB) patients of different severity.

Authors:  Gladys Fiorenza; Liliana Rateni; Miguel A Farroni; Cristina Bogué; Diana G Dlugovitzky
Journal:  Immunol Lett       Date:  2005-04-15       Impact factor: 3.685

5.  Burn trauma induces early HMGB1 release in patients: its correlation with cytokines.

Authors:  János Lantos; Viktor Földi; Elizabeth Roth; György Wéber; Lajos Bogár; Csaba Csontos
Journal:  Shock       Date:  2010-06       Impact factor: 3.454

6.  Emergence of autoantibodies to HMGB1 is associated with survival in patients with septic shock.

Authors:  Stéphanie Barnay-Verdier; Lakhdar Fattoum; Chloé Borde; Srini Kaveri; Sébastien Gibot; Vincent Maréchal
Journal:  Intensive Care Med       Date:  2011-02-26       Impact factor: 17.440

7.  Molecular adjuvant HMGB1 enhances anti-influenza immunity during DNA vaccination.

Authors:  P Fagone; D J Shedlock; H Bao; O U Kawalekar; J Yan; D Gupta; M P Morrow; A Patel; G P Kobinger; K Muthumani; D B Weiner
Journal:  Gene Ther       Date:  2011-05-05       Impact factor: 5.250

8.  HMGB1 is an endogenous immune adjuvant released by necrotic cells.

Authors:  Patrizia Rovere-Querini; Annalisa Capobianco; Paola Scaffidi; Barbara Valentinis; Federica Catalanotti; Marta Giazzon; Ingrid E Dumitriu; Susanne Müller; Matteo Iannacone; Catia Traversari; Marco E Bianchi; Angelo A Manfredi
Journal:  EMBO Rep       Date:  2004-07-23       Impact factor: 8.807

Review 9.  HMGB1 in health and disease.

Authors:  Rui Kang; Ruochan Chen; Qiuhong Zhang; Wen Hou; Sha Wu; Lizhi Cao; Jin Huang; Yan Yu; Xue-Gong Fan; Zhengwen Yan; Xiaofang Sun; Haichao Wang; Qingde Wang; Allan Tsung; Timothy R Billiar; Herbert J Zeh; Michael T Lotze; Daolin Tang
Journal:  Mol Aspects Med       Date:  2014-07-08

Review 10.  The regulation of IL-10 expression.

Authors:  Leona Gabryšová; Ashleigh Howes; Margarida Saraiva; Anne O'Garra
Journal:  Curr Top Microbiol Immunol       Date:  2014       Impact factor: 4.291

View more
  9 in total

1.  High mobility group box 1 protein in bronchoalveolar lavage fluid and correlation with other inflammatory markers in pulmonary diseases.

Authors:  Magda Suchankova; Vladimira Durmanova; Elena Tibenska; Eva Tedlova; Ivan Majer; Helena Novosadova; Juraj Demian; Miroslav Tedla; Maria Bucova
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2018-04-28       Impact factor: 0.670

Review 2.  The Role of HMGB1, a Nuclear Damage-Associated Molecular Pattern Molecule, in the Pathogenesis of Lung Diseases.

Authors:  Mao Wang; Alex Gauthier; LeeAnne Daley; Katelyn Dial; Jiaqi Wu; Joanna Woo; Mosi Lin; Charles Ashby; Lin L Mantell
Journal:  Antioxid Redox Signal       Date:  2019-07-11       Impact factor: 8.401

3.  Interleukin-27 as a Novel Biomarker for Early Cardiopulmonary Failure in Enterovirus 71-Infected Children with Central Nervous System Involvement.

Authors:  Mingyuan Huang; Wenjing Du; Jun Liu; Haiyang Zhang; Longbin Cao; Weiqing Yang; Hui Zhang; Zhiyong Wang; Pei Wei; Weiquan Wu; Zhulin Huang; Ying Fang; Qiling Lin; Xingwen Qin; Zhizhong Zhang; Keyuan Zhou; Jincheng Zeng
Journal:  Mediators Inflamm       Date:  2016-06-15       Impact factor: 4.711

4.  Plasma markers of inflammation and hemostatic and endothelial activity in naturally overweight and obese dogs.

Authors:  R Barić Rafaj; J Kuleš; A Marinculić; A Tvarijonaviciute; J Ceron; Ž Mihaljević; A Tumpa; V Mrljak
Journal:  BMC Vet Res       Date:  2017-01-06       Impact factor: 2.741

Review 5.  Emerging role of HMGB1 in lung diseases: friend or foe.

Authors:  Junying Ding; Xuran Cui; Qingquan Liu
Journal:  J Cell Mol Med       Date:  2016-12-31       Impact factor: 5.310

6.  Down-Regulation of Serum High-Mobility Group Box 1 Protein in Patients with Pulmonary Tuberculosis and Nontuberculous Mycobacterial Lung Disease.

Authors:  Su-Young Kim; Won-Jung Koh; Hye Yun Park; Kyeongman Jeon; Soo-Youn Lee; Jae-Joon Yim; Sung Jae Shin
Journal:  Tuberc Respir Dis (Seoul)       Date:  2017-03-31

7.  Upregulation of miR-196b-5p attenuates BCG uptake via targeting SOCS3 and activating STAT3 in macrophages from patients with long-term cigarette smoking-related active pulmonary tuberculosis.

Authors:  Yaoqin Yuan; Dongzi Lin; Long Feng; Mingyuan Huang; Huimin Yan; Yumei Li; Yinwen Chen; Bihua Lin; Yan Ma; Ziyu Ye; Yuezhi Mei; Xiaolin Yu; Keyuan Zhou; Qunzhou Zhang; Tao Chen; Jincheng Zeng
Journal:  J Transl Med       Date:  2018-10-16       Impact factor: 5.531

8.  High mobility group box-1 (HMGB-1) and its receptors in the pathogenesis of malaria-associated acute lung injury/acute respiratory distress syndrome in a mouse model.

Authors:  Tachpon Techarang; Pitchanee Jariyapong; Parnpen Viriyavejakul; Chuchard Punsawad
Journal:  Heliyon       Date:  2021-12-11

Review 9.  Monocyte Subsets: Phenotypes and Function in Tuberculosis Infection.

Authors:  Pavithra Sampath; Kadar Moideen; Uma Devi Ranganathan; Ramalingam Bethunaickan
Journal:  Front Immunol       Date:  2018-07-30       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.